Stefanie Bolte

6.0k total citations
10 papers, 249 citations indexed

About

Stefanie Bolte is a scholar working on Molecular Biology, Immunology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Stefanie Bolte has authored 10 papers receiving a total of 249 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 6 papers in Immunology and 3 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Stefanie Bolte's work include Immunotherapy and Immune Responses (6 papers), RNA Interference and Gene Delivery (5 papers) and Cancer Research and Treatments (3 papers). Stefanie Bolte is often cited by papers focused on Immunotherapy and Immune Responses (6 papers), RNA Interference and Gene Delivery (5 papers) and Cancer Research and Treatments (3 papers). Stefanie Bolte collaborates with scholars based in Germany, Sweden and Switzerland. Stefanie Bolte's co-authors include Volker T. Heussler, Angelika Sturm, Marc Lütgehetmann, Sebastian Horstmann, Anja Schmidt-Christensen, Joerg‐Matthias Pollok, Claude Libert, Andreas Krueger, Martin Aepfelbacher and Stefanie Graewe and has published in prestigious journals such as Cancer Research, Molecular Microbiology and Infection and Immunity.

In The Last Decade

Stefanie Bolte

10 papers receiving 245 citations

Peers

Stefanie Bolte
Stefanie Bolte
Citations per year, relative to Stefanie Bolte Stefanie Bolte (= 1×) peers Stefanie Graewe

Countries citing papers authored by Stefanie Bolte

Since Specialization
Citations

This map shows the geographic impact of Stefanie Bolte's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stefanie Bolte with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stefanie Bolte more than expected).

Fields of papers citing papers by Stefanie Bolte

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stefanie Bolte. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stefanie Bolte. The network helps show where Stefanie Bolte may publish in the future.

Co-authorship network of co-authors of Stefanie Bolte

This figure shows the co-authorship network connecting the top 25 collaborators of Stefanie Bolte. A scholar is included among the top collaborators of Stefanie Bolte based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stefanie Bolte. Stefanie Bolte is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Schmidt, Marcus, Isabel Vogler, Evelyna Derhovanessian, et al.. (2020). 88MO T-cell responses induced by an individualized neoantigen specific immune therapy in post (neo)adjuvant patients with triple negative breast cancer. Annals of Oncology. 31. S276–S276. 23 indexed citations
2.
Bolte, Stefanie, Katrin Frenzel, Ludwig Heesen, et al.. (2019). Abstract OT2-06-01: Highly innovative personalized RNA-immunotherapy for patients with triple negative breast cancer. Cancer Research. 79(4_Supplement). OT2–6. 6 indexed citations
3.
Heesen, Ludwig, Katrin Frenzel, Stefanie Bolte, et al.. (2019). Abstract CT221: Mutanome engineered RNA immuno-therapy (MERIT) for patients with triple negative breast cancer (TNBC). Cancer Research. 79(13_Supplement). CT221–CT221. 1 indexed citations
4.
Heesen, Ludwig, Katrin Frenzel, Stefanie Bolte, et al.. (2019). Abstract CT221: Mutanome engineered RNA immuno-therapy (MERIT) for patients with triple negative breast cancer (TNBC). Clinical Trials. CT221–CT221. 1 indexed citations
5.
Heesen, Ludwig, Katrin Frenzel, Stefanie Bolte, et al.. (2018). Mutanome engineered RNA immuno-therapy (MERIT) for patients with triple negative breast cancer (TNBC). Annals of Oncology. 29. viii86–viii86. 3 indexed citations
6.
Miller, Matthias, Uğur Şahin, Evelyna Derhovanessian, et al.. (2017). IVAC MUTANOME: A first-in-human phase I clinical trial targeting individual mutant neoantigens for the treatment of melanoma. Annals of Oncology. 28. xi1–xi2. 13 indexed citations
7.
Frenzel, Katrin, Ludwig Heesen, Stefanie Bolte, et al.. (2017). Mutanome engineered RNA immuno-therapy (MERIT) for patients with triple negative breast cancer. Annals of Oncology. 28. xi29–xi29. 2 indexed citations
8.
Sturm, Angelika, Stefanie Graewe, Blandine Franke‐Fayard, et al.. (2008). Alteration of the Parasite Plasma Membrane and the Parasitophorous Vacuole Membrane during Exo-Erythrocytic Development of Malaria Parasites. Protist. 160(1). 51–63. 58 indexed citations
10.
Horstmann, Sebastian, Anja Schmidt-Christensen, Angelika Sturm, et al.. (2005). The liver stage of Plasmodium berghei inhibits host cell apoptosis. Molecular Microbiology. 58(3). 731–742. 123 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026